183 related articles for article (PubMed ID: 19563311)
1. Australia's pharmaceutical cost sharing policy: reducing waste or affordability?
Doran E; Robertson J
Aust Health Rev; 2009 May; 33(2):231-40. PubMed ID: 19563311
[TBL] [Abstract][Full Text] [Related]
2. Impact of cost sharing on prescription drugs used by Medicare beneficiaries.
Goedken AM; Urmie JM; Farris KB; Doucette WR
Res Social Adm Pharm; 2010 Jun; 6(2):100-9. PubMed ID: 20511109
[TBL] [Abstract][Full Text] [Related]
3. Universal Medicine Access through Lump-Sum Remuneration - Australia's Approach to Hepatitis C.
Moon S; Erickson E
N Engl J Med; 2019 Feb; 380(7):607-610. PubMed ID: 30763190
[No Abstract] [Full Text] [Related]
4. American health policy: cracks in the foundation.
Nyman JA
J Health Polit Policy Law; 2007 Oct; 32(5):759-83. PubMed ID: 17855716
[TBL] [Abstract][Full Text] [Related]
5. Distributional impact of higher patient contributions to Australia's Pharmaceutical Benefits Scheme.
Walker A
Aust Health Rev; 2000; 23(2):32-46. PubMed ID: 11010578
[TBL] [Abstract][Full Text] [Related]
6. Drug policy down under: Australia's pharmaceutical benefits scheme.
Duckett SJ
Health Care Financ Rev; 2004; 25(3):55-67. PubMed ID: 15229996
[TBL] [Abstract][Full Text] [Related]
7. The Right to Health: Implications for the Funding of Medicines in Australia.
Harper C; Ghinea N; Lipworth W
J Law Med; 2017; 24(3):640-55. PubMed ID: 30137760
[TBL] [Abstract][Full Text] [Related]
8. A perspective on Australia's National Medicines Policy.
Tett SE
Can J Clin Pharmacol; 2004; 11(1):e28-38. PubMed ID: 15226524
[TBL] [Abstract][Full Text] [Related]
9. Adverse events associated with prescription drug cost-sharing among poor and elderly persons.
Tamblyn R; Laprise R; Hanley JA; Abrahamowicz M; Scott S; Mayo N; Hurley J; Grad R; Latimer E; Perreault R; McLeod P; Huang A; Larochelle P; Mallet L
JAMA; 2001 Jan 24-31; 285(4):421-9. PubMed ID: 11242426
[TBL] [Abstract][Full Text] [Related]
10. The impact of pharmaceutical marketing on market access, treatment coverage, pricing, and social welfare.
Critchley GJ; Zaric GS
Health Econ; 2019 Aug; 28(8):1035-1051. PubMed ID: 31310424
[TBL] [Abstract][Full Text] [Related]
11. Australian pharmaceutical policy: price control, equity, and drug innovation in Australia.
Doran E; Alexander Henry D
J Public Health Policy; 2008 Apr; 29(1):106-20. PubMed ID: 18368023
[TBL] [Abstract][Full Text] [Related]
12. Role of health insurance coverage in women's access to prescription medicines.
Ranji UR; Wyn R; Salganicoff A; Yu H
Womens Health Issues; 2007; 17(6):360-6. PubMed ID: 18042485
[TBL] [Abstract][Full Text] [Related]
13. Assessing the effect of Taiwan's outpatient prescription drug copayment policy in the elderly.
Liu SZ; Romeis JC
Med Care; 2003 Dec; 41(12):1331-42. PubMed ID: 14668666
[TBL] [Abstract][Full Text] [Related]
14. Medicare prescription drug plan costs and affordability--2007.
Davis MM
J Gen Intern Med; 2007 Aug; 22(8):1221-2. PubMed ID: 17497191
[No Abstract] [Full Text] [Related]
15. Does generic entry lower the prices paid for pharmaceuticals in Australia? A comparison before and after the introduction of the mandatory price-reduction policy.
Spinks J; Chen G; Donovan L
Aust Health Rev; 2013 Nov; 37(5):675-81. PubMed ID: 24160374
[TBL] [Abstract][Full Text] [Related]
16. The impact of co-payment increases on dispensings of government-subsidised medicines in Australia.
Hynd A; Roughead EE; Preen DB; Glover J; Bulsara M; Semmens J
Pharmacoepidemiol Drug Saf; 2008 Nov; 17(11):1091-9. PubMed ID: 18942671
[TBL] [Abstract][Full Text] [Related]
17. Management of Newer Antidepressant Medications in U.S. Commercial Health Plans.
Hodgkin D; Horgan CM; Creedon TB; Merrick EL; Stewart MT
J Ment Health Policy Econ; 2015 Dec; 18(4):165-73. PubMed ID: 26729008
[TBL] [Abstract][Full Text] [Related]
18. Impact of type 2 diabetes medication cost sharing on patient outcomes and health plan costs.
Thornton Snider J; Seabury S; Lopez J; McKenzie S; Goldman DP
Am J Manag Care; 2016 Jun; 22(6):433-40. PubMed ID: 27355811
[TBL] [Abstract][Full Text] [Related]
19. Barrier to trade or barrier to profit? Why Australia's Pharmaceutical Benefits Scheme worries U.S. drug companies.
Hamilton C; Lokuge B; Denniss R
Yale J Health Policy Law Ethics; 2004; 4(2):373-85. PubMed ID: 15536919
[No Abstract] [Full Text] [Related]
20. Balancing health and industrial policy objectives in the pharmaceutical sector: lessons from Australia.
Morgan S; McMahon M; Greyson D
Health Policy; 2008 Aug; 87(2):133-45. PubMed ID: 18295927
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
